Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

Cellectar Biosciences (Nasdaq:CLRB), announced on 5/10/18 that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of rhabdomyosarcoma, a rare pediatric cancer.